β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The effectiveness of β2-agonists in the treatment of exacerbations of COPD is already
established. The purpose of this study is to compare the effectiveness of the β2-agonists
alone in nebulization with the association β2-agonists + Ipratropium bromide in the treatment
of an acute exacerbation of COPD consulting the emergency departement based on the clinical
and arterial blood gas.